Exicure Completes Phase 2 Enrollment for GPC-100 in Multiple Myeloma
May 5, 2025
Topline results expected H2 2025 Exicure, Inc., a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient enrollment in its